⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9239557 | 0.73 | — | — | |
| SCHEMBL19395285 | 0.69 | — | — | |
| SCHEMBL26454426 | 0.68 | — | — | |
| SCHEMBL259495 | 0.68 | — | — | |
| SCHEMBL7129181 | 0.67 | — | — | |
| SCHEMBL17333220 | 0.67 | TSHR (0.32) | — | |
| SCHEMBL7120912 | 0.67 | — | — | |
| SCHEMBL17333219 | 0.67 | — | — | |
| SCHEMBL26455300 | 0.67 | — | — | |
| SCHEMBL26454690 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0584347-B1 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS INC (US) | 2003-01-15 | — | — | EP | disclosed |
| US-5965564-A | TREATING OR PREVENTING INFECTION FOLLOWING TREATMENT FOR HEMATOLOGIC MALIGNANCY SUCH AS CHEMOTHERAPY, BY ADMINISTERING A XANTHINE DERIVATIVE WHICH IS 1-SUBSTITUTED WITH AN R ENANTIOMER OMEGA-1 SECONDARY ALCOHOL-SUBSTITUTED ALKYL GROUP | CELL THERAPEUTICS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5792772-A | ADMINISTERING 5-HYDROXYALKYL-3,7-DISUBSTITUTED OR NON-SUBSTITUTED PURINE COMPOUND TO TREAT AUTOIMMUNE DISORDERS | CELL THERAPEUTICS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5739138-A | MODULATORS OF CELLULAR RESPONSE | CELL THERAPEUTICS, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5652243-A | MODULATING CELLULAR RESPONSE | CELL THERAPEUTICS, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5648357-A | MAINTAINING HOMEOSTASIS IN RESPONSE TO INFLAMMATORY AND PROLIFERATIVE STIMULI | CELL THERAPEUTICS, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5629315-A | TREATMENT OF PSORIASIS, ASTHMA,OSTEOPOROSIS, ALCOHOLIC HEPATITIS, AND PREMATURE LABOR | CELL THERAPEUTICS, INC. (US) | 1997-05-13 | — | — | US | disclosed |
| US-5621102-A | REACTING PINANEDIOL CHIRAL DIRECTOR AND HALOALKYL DIALKOXY METALLOID COMPOUND TO UNDERGO HOMOLOGATION REACTION TO FORM INTERMEDIATE, REACTING IT WITH GRIGNARD REAGENT TO FORM SECONDARY ALCHOL, ACYLATING, COUPLING SIDE CHAIN | CELL THERAPEUTICS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5620984-A | Enatiomerically pure hydroxylated xanthine compounds to treat inflammatory diseases | CELL THERAPEUTICS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5612349-A | Enantiomerically pure hydroxylated xanthine compounds to treat shock symptoms | CELL THERAPEUTICS, INC. (US) | 1997-03-18 | — | — | US | disclosed |
| US-5580873-A | ANTITUMOR AGENTS, AIDS THERAPY | CELL THERAPEUTICS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5580874-A | THERAPY FOR SIDE EFFECTS OF IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5567704-A | ADMINISTERING TO TREAT HAIR LOSS CAUSED BY CYTOREDUCTIVE THERAPIES | CELL THERAPEUTICS, INC. (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0584347-A4 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1995-04-26 | — | — | EP | disclosed |
| EP-0584347-A1 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1993017684-A2 | ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |